import { Metadata } from "next";
import { RESEARCH_ARTICLE_CSS } from "@/lib/research-article-css";

export const metadata: Metadata = {
  title: "BPC-157 for Gut Health: What the Research Shows — EVLV",
  description:
    "Preclinical research on BPC-157 and gastrointestinal health: proposed mechanisms, animal model findings, and what the evidence does and does not establish about this synthetic pentadecapeptide.",
  alternates: { canonical: "/research/bpc-157-gut-health" },
};

const INNER_HTML = `
  <span class="kicker">Research Overview · Gastrointestinal</span>
  <h1 itemprop="headline">BPC-157 for Gut Health: What the Research Shows</h1>

  <div class="lead">
    BPC-157 is a synthetic peptide derived from a protein found in human gastric juice that researchers have studied primarily in animal models for its potential effects on gastrointestinal tissue repair and inflammation. Early preclinical evidence suggests it may influence mucosal healing, gut motility, and intestinal blood flow — but robust human clinical trial data does not yet exist to confirm these effects in people.
  </div>

  <h2>Background: What Is BPC-157?</h2>
  <p>Body Protective Compound 157 (BPC-157) is a pentadecapeptide — a chain of 15 amino acids — originally isolated and sequenced from human gastric juice. It is not naturally present in the body in its synthetic form; researchers produce it in laboratory settings for study purposes.</p>
  <p>The compound has been the subject of a substantial volume of preclinical research, primarily from the laboratory of Dr. Predrag Sikiric at the University of Zagreb, spanning roughly three decades. The breadth of this animal-model work is what has drawn interest from the research community and, more recently, from individuals seeking to understand its potential applications under physician guidance.</p>

  <h2>Proposed Mechanisms: What Preclinical Research Hypothesizes</h2>
  <p>Animal studies have proposed several biological pathways through which BPC-157 may affect gastrointestinal tissue. None of these mechanisms are confirmed in humans.</p>

  <h3>Angiogenesis and Mucosal Blood Flow</h3>
  <p>Multiple rodent studies have investigated BPC-157's influence on the formation of new blood vessels (angiogenesis) in damaged gastrointestinal tissue. Researchers have observed increased expression of VEGFR2 (vascular endothelial growth factor receptor) in treated animals, suggesting a possible role in re-establishing tissue perfusion after injury. Sikiric et al. reported this pathway in a series of stomach ulcer studies using rat models with sample sizes of approximately 6–10 animals per group.</p>
  <cite>Sikiric P, et al. Curr Pharm Des. 2018;24(18):1990-2001.</cite>

  <h3>Nitric Oxide System Modulation</h3>
  <p>Preclinical researchers have proposed that BPC-157 interacts with the nitric oxide (NO) system, which plays a role in smooth muscle function, vascular tone, and mucosal protection in the gut. Studies in rat models of gastric and intestinal lesions have shown that BPC-157 administration appeared to counteract NO-deficiency-induced damage and restore normal gut motility patterns — though the exact signaling cascade remains under investigation.</p>

  <h3>Inflammatory Pathway Modulation</h3>
  <p>Studies using rodent models of colitis and bowel lesions have observed reduced inflammatory markers, including decreased NF-κB activation and lower prostaglandin levels, in BPC-157-treated animals compared to controls. A study by Klicek et al. (J Physiol Pharmacol, 2013) examined colon anastomosis healing in rats treated with BPC-157 and reported improved tensile strength and mucosal integrity scores compared to untreated controls, with groups of approximately 8 animals.</p>
  <cite>Klicek R, et al. J Physiol Pharmacol. 2013;64(5):575-583.</cite>

  <h3>Fistula and Anastomosis Healing</h3>
  <p>A notable area of preclinical focus has been the application of BPC-157 in models of intestinal fistulas and surgical anastomoses. Sikiric's group published multiple studies between 2016 and 2020 showing accelerated healing of colocutaneous and gastrocutaneous fistulas in rat models. These studies consistently used groups of 6–10 animals and reported histological improvements in mucosal repair scores.</p>

  <div class="callout">
    <p><strong>Note on these findings:</strong> All mechanisms described above are hypothesized based on animal model data. Translating these findings to human physiology involves significant biological variability. The findings are considered hypothesis-generating, not clinically established.</p>
  </div>

  <h2>Preclinical vs. Human Evidence: What Is and Is Not Established</h2>
  <p>This distinction is critical and should inform how anyone approaches BPC-157 research.</p>

  <h3>What animal research has examined:</h3>
  <p>Rat and mouse models of gastric ulcers, NSAID-induced gut damage, experimentally induced colitis, intestinal anastomosis healing, and short bowel syndrome have all been studied with BPC-157 treatment. Results in these models have generally been favorable across a range of outcome measures including lesion size, mucosal integrity, and inflammatory marker levels.</p>

  <h3>What human clinical evidence does not yet establish:</h3>
  <p>As of the time of writing, there are no large-scale, randomized, placebo-controlled human clinical trials published that confirm BPC-157's effects on human gastrointestinal conditions. A proprietary formulation (PL-10) developed by the Croatian pharmaceutical company Pliva reached early clinical development, but publicly available results from large Phase II or Phase III trials in inflammatory bowel disease have not been published in peer-reviewed literature.</p>
  <p>Case reports and small observational data exist but do not constitute sufficient evidence to draw conclusions about efficacy or safety in human populations. Anyone stating that BPC-157 is proven to "heal" or "treat" any human gut condition is overstating what the current evidence supports.</p>

  <div class="disclaimer">
    <p><strong>Important:</strong> EVLV does not make medical claims about BPC-157. The research described on this page represents preclinical and early-stage scientific investigation. It is not a basis for self-treatment. Any use of BPC-157 or any similar compound in a human context requires evaluation and oversight by a licensed physician.</p>
  </div>

  <h2>Why This Requires Physician Oversight</h2>
  <p>The gap between preclinical findings and confirmed human evidence is precisely why physician oversight is not optional — it is foundational to responsible engagement with compounds like BPC-157.</p>
  <p>A physician evaluating someone's interest in BPC-157 research brings several capabilities that self-research cannot replicate: a complete picture of an individual's health status and contraindications, the ability to assess whether a compound is appropriate given concurrent medications or conditions, oversight of dosing that is calibrated to an individual rather than extrapolated from a rodent study, and monitoring for adverse effects that may not have been captured in small preclinical trials.</p>
  <p>EVLV sells BPC-157 strictly as a research-use-only compound for laboratory and analytical research. We do not sell it for human self-administration, do not provide physician referrals, and do not arrange or supervise clinical protocols. Any human-context application of research compounds is outside EVLV's scope and requires independently obtained physician guidance.</p>
  <p>If you are researching BPC-157 because you are experiencing gastrointestinal symptoms, the appropriate first step is a consultation with a licensed gastroenterologist or a physician familiar with peptide research protocols — not a purchase.</p>

  <hr />

  <h2>Frequently Asked Questions</h2>
  <div itemscope itemtype="https://schema.org/FAQPage">

    <div class="faq-item" itemscope itemprop="mainEntity" itemtype="https://schema.org/Question">
      <div class="faq-q" itemprop="name">What conditions has BPC-157 been studied for in gut health research?</div>
      <div class="faq-a" itemprop="acceptedAnswer" itemscope itemtype="https://schema.org/Answer">
        <span itemprop="text">Preclinical researchers have studied BPC-157 in animal models of gastric ulcers, NSAID-induced gastrointestinal damage, experimentally induced colitis, intestinal fistulas, and post-surgical anastomosis healing. These findings have not been replicated in large-scale human clinical trials, so no condition has been confirmed as treatable with BPC-157 in a human medical context.</span>
      </div>
    </div>

    <div class="faq-item" itemscope itemprop="mainEntity" itemtype="https://schema.org/Question">
      <div class="faq-q" itemprop="name">Is BPC-157 FDA-approved for any gastrointestinal condition?</div>
      <div class="faq-a" itemprop="acceptedAnswer" itemscope itemtype="https://schema.org/Answer">
        <span itemprop="text">No. BPC-157 is not FDA-approved for any medical condition. It is available as a compounded research compound under physician supervision in the United States. Products sold for research use only, like those through EVLV, are not intended for human self-administration.</span>
      </div>
    </div>

    <div class="faq-item" itemscope itemprop="mainEntity" itemtype="https://schema.org/Question">
      <div class="faq-q" itemprop="name">What makes BPC-157 different from standard gut health supplements?</div>
      <div class="faq-a" itemprop="acceptedAnswer" itemscope itemtype="https://schema.org/Answer">
        <span itemprop="text">BPC-157 is a synthetic peptide, not a traditional supplement. Unlike over-the-counter digestive products, it is studied for direct effects on tissue-level repair mechanisms, angiogenesis, and inflammatory signaling in animal models — pathways that dietary supplements do not typically address. This also means its use requires physician oversight rather than consumer self-dosing.</span>
      </div>
    </div>

    <div class="faq-item" itemscope itemprop="mainEntity" itemtype="https://schema.org/Question">
      <div class="faq-q" itemprop="name">Are there published human studies on BPC-157 and gut health?</div>
      <div class="faq-a" itemprop="acceptedAnswer" itemscope itemtype="https://schema.org/Answer">
        <span itemprop="text">Large-scale human randomized controlled trials have not been published in peer-reviewed literature as of this writing. A proprietary BPC-157 formulation (PL-10) was explored in early pharmaceutical development for inflammatory bowel disease in Croatia, but full Phase II/III results are not publicly available. The existing human data is limited to small case series and observational reports.</span>
      </div>
    </div>

    <div class="faq-item" itemscope itemprop="mainEntity" itemtype="https://schema.org/Question">
      <div class="faq-q" itemprop="name">Does EVLV provide medical guidance or physician referrals for BPC-157?</div>
      <div class="faq-a" itemprop="acceptedAnswer" itemscope itemtype="https://schema.org/Answer">
        <span itemprop="text">No. EVLV is a research-use-only vendor. We sell laboratory and analytical research compounds and publish independent third-party batch documentation. We do not provide medical advice, physician referrals, or supervised clinical protocols. Researchers considering any human-context application of BPC-157 should consult an independently obtained licensed physician.</span>
      </div>
    </div>

    <div class="faq-item" itemscope itemprop="mainEntity" itemtype="https://schema.org/Question">
      <div class="faq-q" itemprop="name">Can I use BPC-157 to treat a specific gut condition I have?</div>
      <div class="faq-a" itemprop="acceptedAnswer" itemscope itemtype="https://schema.org/Answer">
        <span itemprop="text">BPC-157 is not approved to treat any condition, and EVLV does not position it as a treatment. EVLV sells BPC-157 for laboratory and analytical research only. If you have an active gastrointestinal condition, consult a licensed gastroenterologist independently — EVLV does not provide medical guidance or physician referrals.</span>
      </div>
    </div>

  </div>

  <div class="cta-block">
    <h2>Research starts with documentation.</h2>
    <p>Browse EVLV's catalog with lot-level COA documentation — independent purity and identity data you can verify before you order.</p>
    <a href="/coas" class="cta-btn">View COA Library</a>
  </div>
`;

const articleJsonLd = {
  "@context": "https://schema.org",
  "@type": "Article",
  headline: "BPC-157 for Gut Health: What the Research Shows",
  description:
    "Preclinical research on BPC-157 and gastrointestinal health: proposed mechanisms, animal model findings, and what the evidence does and does not establish.",
  author: { "@type": "Organization", name: "EVLV" },
  publisher: { "@type": "Organization", name: "EVLV" },
  mainEntityOfPage: {
    "@type": "WebPage",
    "@id": "https://www.evlvpeptides.com/research/bpc-157-gut-health",
  },
};

export default function Page() {
  return (
    <>
      <style>{RESEARCH_ARTICLE_CSS}</style>
      <script
        type="application/ld+json"
        dangerouslySetInnerHTML={{ __html: JSON.stringify(articleJsonLd) }}
      />
      <article
        className="evlv-rc"
        itemScope
        itemType="https://schema.org/Article"
        dangerouslySetInnerHTML={{ __html: INNER_HTML }}
      />
    </>
  );
}
